Form 4: Fairmount Funds Boosts Zenas BioPharma Stake

Fairmount Funds Management LLC and related entities increased their beneficial ownership in Zenas BioPharma, Inc. by purchasing 316,219 shares of common stock at $19 per share.

Summary

• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, and Peter Evan Harwin reported an acquisition of Zenas BioPharma, Inc. (ZBIO) common stock.
• The transaction involved the purchase of 316,219 shares of common stock on October 7, 2025.
• Each share was acquired at a price of $19, totaling approximately $6,008,161.
• Following this transaction, Fairmount Healthcare Fund II L.P. indirectly beneficially owns 2,209,025 shares of Zenas BioPharma common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Tomas Kiselak, a Managing Member of Fairmount Funds Management LLC, serves on the board of directors of Zenas BioPharma, leading to Fairmount being deemed a director by deputization.

Sentiment

Score: 8

Explanation: The significant purchase of common stock by a director and major shareholder, especially under a 10b5-1 plan, indicates strong insider confidence in the company's valuation and future prospects, which is a positive signal for investors.

Positives

• Increased insider ownership signals confidence in the company's future prospects from a significant shareholder and director.
• The purchase was substantial, involving over $6 million, indicating a strong conviction at the current share price of $19.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Fairmount Funds Management LLC, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

Industry Context

This insider transaction reflects a specific investment decision by a significant shareholder and director within the biopharmaceutical sector. While not directly indicative of broader industry trends, it suggests confidence in Zenas BioPharma's specific trajectory within the competitive biopharma landscape.

Corporate Governance

Related Party Transactions

• The acquisition of 316,219 shares of common stock by Fairmount Funds Management LLC and related entities, including individuals who serve as directors of Zenas BioPharma, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view this significant insider purchase as a positive indicator of future performance and management confidence, potentially boosting investor sentiment.
• The transaction reinforces the commitment of a major institutional investor to the company's long-term success.

Key Dates

Recommendation

The substantial purchase of Zenas BioPharma shares by Fairmount Funds Management LLC, a significant shareholder and entity with board representation, signals strong insider confidence in the company's current valuation and future outlook. Such a large investment by a knowledgeable party often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Zenas BioPharma, ZBIO, Fairmount Funds Management, Insider Trading, Stock Purchase, Form 4, Beneficial Ownership, Biopharma